H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...